Loading...

    Explore
    • Policy Monitoring
    • Live Policy Feed
    • Billing Codes
    • Healthcare Providers
    • Health Insurance Payers
    • States
    • Service Lines
    • Taxonomy Codes
    Lookup tools
    • Billing Code Lookup
    • CPT Modifier Lookup
    • Provider Taxonomy Code Lookup
    • Healthcare Provider & Facility Lookup
    • Health Insurance Payer Lookup
    • Payer Contact Directory

    Policy & Benchmark Tools

    • Prior Authorization Lookup
    • Coverage Criteria Lookup
    • Timely Filing Lookup
    • Billing Code Reimbursement Rates
    • Payer Comparison Dashboard
    • Facility Comparison Dashboard
    • All tools

    Company

    • About OpenPayer
    • Data Sources
    • Request a Policy / Feedback
    • Trek Health
    OpenPayerby Trek Health
    LinkedInYouTube

    © 2026 Trek Health. All rights reserved.

    OpenPayer is built and maintained by Trek Health.

    v1.0.31
    OpenPayerPolicy UpdatesLaboratory/PathologyAetna flow cytometry coverage update | OpenPayer
    Ask Trek AI about this page
    CurrentAetnaPolicy 0351

    Flow Cytometry, Ektacytometry, DNA Ploidy, and S-phase Fraction

    Customize your policy alerts

    Sign up for Aetna Policy 0351 alerts

    Get alerted when Policy 0351 changes without checking for updates manually.

    Monitor payer policy activity

    Receive email alerts as soon as relevant payer policies are published or updated.

    Clinical coverage and medical necessity policy for use of flow cytometry (cell surface markers, DNA ploidy, S‑phase fraction) and ektacytometry, including indications considered medically necessary, investigational/experimental exclusions, and coding guidance affecting ordering clinicians and laboratories.

    OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.

    Policy Summary
    PayerAetna
    PolicyFlow Cytometry, Ektacytometry, DNA Ploidy, and S-phase Fraction
    Policy CodePolicy 0351
    Change TypeNo material change
    Effective DateJun 15, 2001
    Last ReviewJun 5, 2023
    Next Review DateApr 11, 2024
    Key ActionDocument that prognostic information from DNA ploidy/S‑phase testing will affect treatment decisions when ordering these tests for the listed localized cancers.
    SourceLink
    POLICY UPDATE CHANGES

    No material clinical or coverage changes in this revision.

    15+medically necessary indications listed for flow cytometry
    9localized cancers eligible for conditional ploidy/S‑phase use
    93.85%OGE sensitivity (HS)
    98.38%OGE specificity (HS)
    multiplecodes listed (CPT/HCPCS/ICD-10)

    Coverage Criteria

    inv-01: Flow cytometry (cell surface markers) — Medically necessary

    Covered when ANY of the following indications are present.

    Flow cytometry (cell surface markers) medical necessity list: 1. Abnormal tissue, bone marrow, or blood histology suspicious for lymphoma, leukemia, or myelodysplastic syndrome when distinction between reactive and neoplastic conditions is required; OR 2. B‑cell monitoring for immunosuppressive disorders; OR 3. Hairy cell monitoring; OR 4. Hereditary persistence of fetal hemoglobin (HPFH) with unexplained increased hemoglobin F; OR 5. Hereditary spherocytosis with Coombs‑negative hemolytic anemia; OR 6. Immunophenotyping for leukemia, lymphoma, or myelodysplastic syndrome; OR 7. Mast cell disease; OR 8. Measurement of CD4/CD8 ratio from bronchoalveolar lavage fluid for sarcoidosis diagnosis; OR 9. Multiple myeloma; OR 10. Myeloproliferative neoplasms for workup of progression or transformation to acute myeloid leukemia (AML); OR 11. Paroxysmal nocturnal hemoglobinuria; OR 12. Post‑operative monitoring after organ transplantation; OR 13. Primary immunodeficiencies; OR 14. Sezary syndrome (diagnosis); OR 15. T‑cell monitoring for HIV/AIDS.

    Extracted verbatim list of indications from policy.

    inv-02: DNA ploidy and S‑phase fraction — Conditional medical necessity

    Covered when ALL of the following are met.

    DNA ploidy/S‑phase for localized cancers: Measurement of flow cytometry‑derived DNA content (ploidy) or S‑phase fraction is medically necessary for the listed localized cancers ONLY when the obtained prognostic information will affect treatment decisions.Usually once per tumor lifetime

    Eligible localized cancers: endometrial adenocarcinoma; gastric cancer; mediastinal neuroblastoma; medulloblastoma; ovarian carcinoma; partial hydatidiform mole; prostatic adenocarcinoma; renal cell adenocarcinoma; urinary bladder carcinoma.

    inv-03: Ektacytometry — Medically necessary

    Covered when ALL of the following are met.

    Ektacytometry for RBC disorders: Ektacytometry is medically necessary for diagnosis of red blood cell (RBC) cytoskeleton and hydration disorders (e.g., hereditary spherocytosis, pyro‑poikilocytosis, stomatocytosis, ovalocytosis, elliptocytosis, xerocytosis) when RBC morphology does not provide a clear diagnosis.

    OGE is a screening/diagnostic test with reported high sensitivity and specificity for HS in validation studies; test codes include 0305U and relevant ICD‑10 codes such as D58.0.

    inv-04: Experimental and investigational

    Not covered (considered experimental/investigational) for the following.

    Experimental/investigational procedures: 1. RBC adhesion index measurements (e.g., Hypoxic BioChip Adhesion, Normoxic BioChip Adhesion) are experimental/investigational for all indications; OR 2. Flow cytometry‑derived DNA content (ploidy) or S‑phase fraction is experimental/investigational for cancers including, but not limited to, breast cancer; cervical cancer; colorectal cancer; non‑small cell lung cancer; pediatric intracranial tumors; and small cell lung cancer.

    Effectiveness not established per policy.

    Flow cytometry‑derived DNA ploidy and S‑phase fraction (SPF) testing is considered experimental/investigational and not covered for multiple solid tumor types listed in this policy because effectiveness for these indications has not been established. Specific cancers named as not covered include, but are not limited to, breast cancer, cervical cancer, colorectal cancer, non‑small cell lung cancer, pediatric intracranial tumors, and small cell lung cancer.

    Guideline summaries cited in the policy (ASCO and related updates) note insufficient evidence to support routine use of flow cytometry‑derived DNA/ploidy measures in clinical practice for breast cancer, and explicitly state that DNA ploidy or % S‑phase by flow cytometry should not be used to determine prognosis of early‑stage colorectal cancer. The policy therefore restricts routine application of these tests except where specified conditions apply.

    Validation studies of the BIOCHIP mosaic‑based IIF assay have significant limitations that affect generalizability and clinical adoption: reported studies were performed in a limited number of countries, often enrolled small sample sizes (for example, a cross‑sectional study with n = 40), and recruited largely Caucasian normal controls. Additional reported drawbacks include low case‑to‑control ratios, selection bias, and in some studies an absence of direct comparison with established methods such as ELISA. These limitations support the conclusion that BIOCHIP assays require broader, prospective validation across diverse populations before routine clinical use can be recommended.

    Based on the NIH consensus and the evidence summarized in this policy, the routine use of flow cytometry‑derived DNA content (ploidy) or S‑phase fraction for prognostic or therapeutic decision making in cancers is not indicated except for the small set of localized tumors specifically listed when results will affect treatment decisions.

    Professional society guidance and the policy narrative do not support routine application of DNA ploidy or S‑phase fraction testing for prognosis in several tumor types. ASCO updates and related guideline statements cite insufficient evidence for routine DNA/ploidy testing in breast cancer and recommend against using flow‑cytometrically derived DNA ploidy or % S‑phase to determine prognosis for early‑stage colorectal cancer; the policy extends noncoverage/experimental status to other cancers where effectiveness has not been established.

    Covered Indications and Use Cases

    inv-37: See flow cytometry medically necessary indications (cell surface markers), conditional use of DNA ploidy/S‑phase for listed localized cancers when results will affect treatment, and ektacytometry for RBC cytoskeleton/hydration disorders when morphology is inconclusive.

    See flow cytometry medically necessary indications (cell surface markers); DNA ploidy/S‑phase testing is conditional for listed localized cancers when results will affect treatment; ektacytometry is indicated for RBC membrane/cytoskeleton disorders when morphology is inconclusive.

    Summary guidance: Refer to flow cytometry cell surface marker indications for covered uses; for DNA ploidy/S‑phase fraction, coverage applies only for specified localized cancers when documented prognostic information will influence treatment decisions; ektacytometry is covered for RBC membrane/hydration disorders when morphology is non-diagnostic.

    See policy sections for full lists and test frequency limits.

    inv-38: Diagnosis and differential diagnosis of hereditary spherocytosis and other RBC membrane disorders — OGE diagnostic performance cited

    Covered when ALL of the following are met.

    OGE for diagnosis of HS and RBC membrane disorders:

    Coding and Billing

    Covered CPT Codes (if selection criteria are met)CPTCovered
    86360T cells; absolute CD4 and CD8 count, including ratio.
    88182Flow cytometry, cell cycle or DNA analysis.
    88184Flow cytometry, cell surface, cytoplasmic, or nuclear marker, technical component only; first marker.
    88185each additional marker (List separately in addition to code for first marker).
    88187Flow cytometry, interpretation; 2 to 8 markers.
    881889 to 15 markers.
    8818916 or more markers.
    CPT/HCPCS Codes labeled not covered or experimental for listed indicationsHCPCSNot Covered
    0303UHematology, red blood cell (RBC) adhesion to endothelial/subendothelial adhesion molecules, functional assessment, whole blood, with algorithmic analysis and result reported as an RBC adhesion index; hypoxic.
    0304UHematology, red blood cell (RBC) adhesion to endothelial/subendothelial adhesion molecules, functional assessment, whole blood, with algorithmic analysis and result reported as an RBC adhesion index; normoxic.
    0305UHematology, red blood cell (RBC) functionality and deformity as a function of shear stress, whole blood, reported as a maximum elongation index.
    ICD‑10 Codes covered if selection criteria are metICD-10Covered
    B20Human immunodeficiency virus [HIV] disease [T cell monitoring].
    C16.0 - C16.9Malignant neoplasm of stomach [gastric, localized without metastatic disease].
    C38.1 - C38.2Malignant neoplasm of anterior and posterior mediastinum [neuroblastoma, localized without metastatic disease].
    C54.1Malignant neoplasm of endometrium [localized without metastatic disease].
    C56.1 - C56.9Malignant neoplasm of ovary [localized without metastatic disease].
    C57.4Malignant neoplasm of uterine adnexa, unspecified [localized without metastatic disease].
    C61Malignant neoplasm of prostate.
    C64.1 - C64.9Malignant neoplasm of unspecified kidney, except renal pelvis [localized without metastatic disease].
    C67.0 - C67.9Malignant neoplasm of bladder [localized without metastatic disease].
    C71.0 - C71.9Malignant neoplasm of brain [medulloblastoma in adults only].
    1–10 of 33
    1/4
    ICD‑10 Codes explicitly listed as not covered for DNA ploidy/S‑phase indicationsICD-10Not Covered
    C18.0 - C21.8Malignant neoplasm of colon, rectosigmoid junction, rectum, anus and anal canal.
    C34.00 - C34.92Malignant neoplasm of bronchus and lung [non-small cell lung cancer].
    C50.011 - C50.929Malignant neoplasm of breast.
    C53.0 - C53.9Malignant neoplasm of cervix uteri.
    D43.0 - D43.3Neoplasm of uncertain behavior of brain and cranial nerves [pediatric intracranial only].
    Covered CPT CodesCPT
    No codes listed
    Test frequency per tumor lifetime — DNA ploidy / S‑phase fraction
    Frequency ruleUsually performed only once per tumor lifetime, typically after diagnosis and before treatment.
    Applies toFlow cytometry-derived DNA content (ploidy) and S‑phase fraction testing for listed localized cancers.
    Typical timingOrdered after a definitive diagnosis is made and prior to initiation of definitive therapy.
    RationaleSingle testing is sufficient because results are intended to provide prognostic information that would affect initial treatment decisions rather than serial monitoring.
    Exceptions notedRe-testing not generally recommended; any repeat testing would require documentation that additional results could alter treatment management.

    Provider Actions and Administrative Notes

    Prior Authorization

    Verify code‑specific coverage criteria and billing codes

    Certain CPT/HCPCS procedure codes are listed as covered only when the policy's clinical selection criteria are met; verify coverage and any authorization requirements prior to billing.

    • Covered codes contingent on meeting selection criteria: 86360, 88182, 88184, 88185, 88187, 88188, 88189.
    • Codes labeled not covered/experimental for listed indications: 0303U, 0304U, 0305U.
    Note

    Prior authorization not specified in policy excerpt

    The policy text does not specify any prior authorization requirements for the tests in this excerpt; confirm payer-specific prior auth rules separately if needed.

    Note

    Ordering Requirements

    Documentation Required

    Document clinical indication and expected treatment impact

    Document the clinical indication and medical necessity when ordering DNA ploidy or S‑phase fraction testing; specifically state that results will influence treatment decisions.

    • Policy: DNA ploidy/S‑phase medically necessary for listed localized cancers ONLY when prognostic information will affect treatment decisions.
    • Provider should document clinical indication supporting medical necessity.
    Note

    No explicit ordering privileges or provider‑type requirements

    The policy does not specify any provider-type ordering privileges or restrictions; tests are discussed in the context of specialist workups but no explicit ordering privileges are listed.

    • Tests are described in specialist contexts (e.g., bone marrow workup, BAL for pulmonary disease, tumor evaluation) but no explicit provider-type requirements are stated.

    Not Covered / Experimental

    The policy lists specific procedure codes and test types that are not covered because they are considered experimental or investigational. Examples include RBC adhesion index assays billed with HCPCS codes 0303U and 0304U, and flow cytometry‑derived DNA ploidy/S‑phase testing when ordered for cancers identified in the experimental/investigational list (e.g., breast, cervical, colorectal, non‑small cell lung, pediatric intracranial tumors, small cell lung cancer).

    Routine ordering of flow cytometry for DNA ploidy or S‑phase fraction as prognostic tests in cancers is not supported by guideline statements and is therefore listed as not covered for those routine prognostic uses (for example, breast cancer and early‑stage colorectal cancer). Coverage is limited to the specific localized cancers enumerated in the policy when prognostic results will influence treatment decisions.

    BIOCHIP assays are described as promising but currently not recommended for routine clinical use without further validation. The policy highlights study limitations — small sample sizes, selection bias, and limited ethnic diversity among controls — which may preclude coverage of BIOCHIP testing for diagnostic purposes until larger, prospective, and comparative validation studies are available.

    Definitions

    DNA index (DI)
    DefinitionRatio of the mean tumor G0/G1 DNA content to that of normal diploid reference cells.
    InterpretationA DI deviating from 1 indicates aneuploidy (gain or loss of chromosomal content).
    Use caseUsed as a quantitative expression of tumor DNA content in flow cytometric analysis of solid tumors.
    S‑phase fraction (SPF)
    DefinitionPercentage of cells actively duplicating DNA (in S-phase) prior to mitosis.
    Clinical correlationHigher SPF often correlates with poorer differentiation, larger tumor size, and greater aggressiveness, though standards vary.

    Background and Evidence Limitations

    Multiple limitations in the BIOCHIP evidence base reduce confidence in its diagnostic performance: studies were conducted in a small number of countries, validation cohorts often recruited only Caucasian normal controls, sample sizes were small, and some studies lacked comparisons to established assays (e.g., ELISA). Review authors emphasize the need for prospective studies with more diverse control populations and larger case‑control ratios to validate BIOCHIP performance.

    Summarizing the evidence, the policy states that the routine use of flow cytometry‑derived DNA content (ploidy) or S‑phase fraction for prognostic or therapeutic purposes in cancers is not indicated except for the narrow list of localized tumors for which the policy allows conditional use when results will affect treatment decisions. Guideline statements (ASCO) and the NIH consensus are cited to support this stance.

    Revision History

    2001-06-15policy_effective

    Policy originally became effective.

    2001-06-15references_added

    Initial policy established coverage framework for flow cytometry, ektacytometry, DNA ploidy, and S-phase fraction testing.

    2023-06-05policy_review

    Policy underwent routine review (last review date recorded).

    Policy Summary
    PayerAetna
    PolicyFlow Cytometry, Ektacytometry, DNA Ploidy, and S-phase Fraction
    Policy CodePolicy 0351
    Change TypeNo material change
    Effective DateJun 15, 2001
    Last ReviewJun 5, 2023
    Next Review DateApr 11, 2024
    Key ActionDocument that prognostic information from DNA ploidy/S‑phase testing will affect treatment decisions when ordering these tests for the listed localized cancers.
    SourceLink
    On This Page
    Coverage CriteriaCovered Indications and Use CasesCoding and BillingProvider Actions and Administrative NotesOrdering RequirementsNot Covered / ExperimentalDefinitionsBackground and Evidence LimitationsRevision History
    Osmotic gradient ektacytometry (OGE) may be used for diagnosis and differential diagnosis of hereditary spherocytosis and other RBC membrane disorders; validation studies report high diagnostic performance (e.g., sensitivity 93.85% and specificity 98.38% for HS in Llaudet‑Planas et al. 2018).

    OGE parameters and cutoffs described in cited validation studies; use when routine morphology and standard laboratory tests are inconclusive.

    inv-39: Adjunctive evaluation in suspected pulmonary sarcoidosis using BAL lymphocyte subpopulation analysis (CD4/CD8 ratio)

    Covered when the following adjunctive criterion is met.

    BAL lymphocyte subpopulation analysis for sarcoidosis: Measurement of BAL CD4/CD8 ratio (e.g., CD4/CD8 > 3.5) is an adjunctive evaluation supportive of pulmonary sarcoidosis diagnosis when clinical and radiographic features are consistent; a CD4/CD8 ratio greater than 3.5 has been reported with high specificity (~94%).CD4/CD8 ratio > 3.5

    Used as adjunctive evidence; not solely diagnostic.

    inv-40: Research/assay development for platelet/leukocyte adhesion and monitoring therapeutic effects (e.g., vaso-occlusive crisis therapies)

    Covered only for research or investigational use.

    Microfluidic adhesion assays - research use: Microfluidic BioChip assays for platelet/leukocyte adhesion are considered investigational; they may be used in research or assay development to study adhesion biology and to explore monitoring of therapeutic effects (e.g., assessing response to crizanlizumab in vaso‑occlusive crisis therapy).

    Policy lists these approaches as experimental/investigational for clinical use due to unestablished effectiveness.

    inv-41: Serologic testing for pemphigus and related autoimmune blistering disease using BIOCHIP mosaic IIF — limited validation studies

    Covered in limited validation contexts; broader validation needed before routine adoption.

    BIOCHIP mosaic IIF for pemphigus and related AIBD: BIOCHIP mosaic‑based indirect immunofluorescence (IIF) serologic testing demonstrates high sensitivity and specificity in limited validation studies for pemphigus and related autoimmune blistering diseases, but studies are small and lack diverse control populations; further validation is required before routine clinical use.

    Validation studies cited from multiple countries; limitations include small sample sizes and limited ethnic diversity.

    inv-42: Screening and evaluation of hereditary spherocytosis and other red blood cell membrane disorders — OGE cited (Llaudet-Planas 2018; Huisjes 2020)

    Covered when ALL of the following are met.

    OGE screening/evaluation for HS and RBC membrane disorders: Osmotic gradient ektacytometry may be used for screening and evaluation of hereditary spherocytosis and other red blood cell membrane disorders; cited references (Llaudet‑Planas 2018; Huisjes 2020) support its diagnostic utility.

    Use when standard testing is inconclusive; reported diagnostic metrics available in cited literature.

    inv-43: Serologic diagnosis and evaluation of autoimmune blistering diseases (pemphigus vulgaris/foliaceus/bullous pemphigoid) — BIOCHIP mosaic IIF evidence summarized

    Covered in investigational/limited-validation contexts.

    BIOCHIP serologic diagnosis for AIBD: BIOCHIP mosaic IIF shows promising sensitivity and specificity for pemphigus vulgaris, pemphigus foliaceus, and bullous pemphigoid in small validation studies but requires further investigation before routine clinical adoption.

    Studies cited include cross‑sectional comparisons with direct immunofluorescence and ELISA; limitations noted in policy background.

    inv-44: Prognostic assessment in various solid tumors using DNA ploidy and S-phase fraction — multiple cited references

    Covered when ALL of the following are met.

    DNA ploidy/S‑phase prognostic assessment: Flow cytometric DNA ploidy and S‑phase fraction have been studied as prognostic markers across multiple solid tumors (colorectal, breast, ovarian, prostate, gastric, bladder, renal, medulloblastoma, neuroblastoma); numerous references summarize this research but routine use is limited and coverage is conditional as specified in policy.

    See policy reference list for extensive citations regarding prognostic studies.

    No explicit prior authorization or impacted codes listed

    No explicit prior authorization requirements or affected billing codes are stated in the supplied excerpt; check administrative/billing resources for plan-specific rules before ordering.

    Documentation Required

    Document expected impact on treatment decisions

    When ordering DNA ploidy or S‑phase fraction testing, document that the prognostic information obtained will affect treatment decisions for the patient.

    • Policy: DNA ploidy/S‑phase is medically necessary for listed localized cancers ONLY when prognostic information will affect treatment decisions.
    • Test is usually performed only once per tumor lifetime, typically after diagnosis and before treatment.
    Documentation Required

    BIOCHIP validation and study limitations

    BIOCHIP mosaic‑based IIF validation is limited by small sample sizes, selection bias, and lack of ethnically diverse control populations; note these limitations when ordering or interpreting BIOCHIP results.

    • Validation studies performed in limited countries and with primarily Caucasian control populations.
    • Some studies had small sample sizes (e.g., n=40) and lacked comparison with ELISA in all cases.
    Denial Risk

    Denial risk for non‑supported indications

    Testing for DNA ploidy or S‑phase fraction for routine prognostic or therapeutic purposes is considered not indicated except for the listed localized cancers; ordering for unsupported indications may be denied.

    • Policy: routine use of DNA ploidy/S‑phase for prognosis/therapy not indicated; experimental/investigational for cancers such as breast, cervical, colorectal, NSCLC, pediatric intracranial tumors, and small cell lung cancer.
    • Order only when the policy's medical necessity criteria are met to avoid claim denial.
    Denial Risk

    Tests not supported by clinical guidelines for routine management

    Specialty guidelines and cited reviews do not recommend routine use of flow cytometry‑derived DNA ploidy or S‑phase fraction for prognosis in many cancers; avoid using these tests for management decisions unless policy exceptions apply.

    • ASCO and guideline updates note insufficient evidence to support routine use of DNA/ploidy by flow cytometry for breast cancer and early‑stage colorectal cancer.
    • Authors and guideline statements cited in the policy conclude these measures are not indicated for routine prognostic management.
    Note

    Consult full policy for additional provider actions

    Fallback: consult the full policy/source document for any additional provider requirements or clarifications not captured in this excerpt.

    Note

    Refer to complete source document

    Fallback: review the full document source for any missing administrative or billing instructions not present in this chunk.

    Note

    Verify policy history and coding details in source

    Fallback: check the complete policy history and coding tables in the full source for updates or code-specific notes not in this excerpt.

    Documentation Required

    Ordering documentation — document medical necessity and clinical impact

    There are no explicit ordering documentation requirements listed in these chunks beyond documenting medical necessity and, for DNA ploidy/S‑phase testing, documenting intended impact on treatment decisions.

    • Policy requires documentation that prognostic information will affect treatment decisions for DNA ploidy/S‑phase testing.
    • No other specific ordering paperwork, provider-type privileges, or forms are specified in the provided excerpts.
    Note

    No extra provider actions specified

    No additional provider actions are specified in this document excerpt; follow the policy's medical necessity criteria and local administrative rules when ordering and billing.

    Measurement limitations
    SPF measurement is technically difficult with lack of standardized methodologies and variable cutoff definitions between labs.
    Osmotic gradient ektacytometry (OGE)
    MethodLaser diffraction viscometry measuring RBC deformability across an osmotic gradient (OGE/osmoscan).
    Parameters reportedDeformability profile across osmotic gradient, osmotic fragility, and hydration status of RBC populations.
    Clinical usePart of laboratory diagnosis for hereditary spherocytosis and other RBC membrane/hydration disorders when morphology is inconclusive.
    DNA ploidy / S-phase fraction (SPF) by flow cytometry
    Test descriptionFlow cytometric measurement of nuclear DNA content (ploidy) and proportion of cells in S-phase (proliferation index).
    Clinical contextUsed experimentally as prognostic or diagnostic markers in various tumors; evidence is mixed and not routinely indicated except in specified localized cancers when results will affect treatment.
    OutputDNA histogram peaks (diploid vs aneuploid), DNA index (DI), and S‑phase fraction (SPF).
    Microfluidic adhesion assay / BioChip
    Assay typeEx‑vivo microfluidic assays (BioChip) that measure platelet or leukocyte adhesion under controlled flow conditions.
    OutputsQuantitative adhesion indices and imaging of thrombus formation or leukocyte rolling/firm adhesion.
    Current statusInvestigational for clinical use; useful in research and to evaluate drug effects (e.g., crizanlizumab) and potential to monitor therapeutic response.
    BIOCHIP mosaic-based IIF
    TechniqueIndirect immunofluorescence (IIF) using a mosaic of substrates (BIOCHIP) to detect characteristic staining patterns in a single incubation field.
    ApplicationSerologic testing for autoimmune blistering diseases such as pemphigus vulgaris and foliaceus.
    Validation limitationsValidation studies show high sensitivity/specificity but are limited by small sample sizes and lack of diverse ethnic control populations; further validation needed.
    BIOCHIP mosaic-based IIF
    DescriptionSerologic indirect immunofluorescence using mosaic substrates to detect target antigens and staining patterns across multiple substrates in one slide.
    Clinical utilityDemonstrated relatively high sensitivity and specificity in limited studies for pemphigus antibodies (Dsg1/Dsg3) compared with ELISA/IIF.
    Evidence gapsStudies performed in limited countries with primarily Caucasian controls; broader validation across ethnicities is needed before routine use.
    Osmotic gradient ektacytometry
    PurposeRBC deformability test used to screen for hereditary spherocytosis and other red cell membrane disorders.
    Method summaryMeasures red blood cell deformability across an osmotic gradient (OGE/osmoscan) and reports deformability, osmotic fragility, and hydration metrics.
    Clinical evidenceCited studies (e.g., Llaudet-Planas 2018; Huisjes 2020) support OGE as a valuable screening/diagnostic test for HS with high sensitivity and specificity in cited literature.
    DNA ploidy / S‑phase fraction — Frequency limit
    Frequency limitUsually once per tumor lifetime.
    Typical timingPerformed after diagnosis and before initiation of treatment.
    Applies toFlow cytometry-derived DNA ploidy and S‑phase fraction testing when used for prognostic assessment in tumors per policy criteria.

    Flow cytometry separates and quantifies cell populations using cell surface phenotype and fluorescence‑based measurements, and can measure nuclear DNA content (ploidy) and the percentage of cells in S‑phase (SPF) to estimate proliferation. Osmotic gradient ektacytometry measures red blood cell deformability and hydration (e.g., osmoscan/OGE), producing parameters such as elongation index that help diagnose RBC membrane and hydration disorders when morphology is inconclusive.

    2024-04-11next_review_scheduledLatest

    Next policy review scheduled.